1[1]Lodge J,Ammoni B,Prasad K,et al.Ex-vivo and in situ-restection of inferior vena cava with hepatectomy for colorectal metastases[J].Ann Surg,2000,231:471～479
2[2]Helm J,Choi J,Sutphen R,et al.Current and evolving strategies for colorectal cancer screening[J].Cancer Control,2003,10(3):193～204
3[3]Michael BN,Joel S and David M.Current management of malignant large-bowel obstruction[J].Contemporarysurgery,2002,58:396～400
4[4]Kantorova I,Lipska L,Belohlavek O,et al.Routine(18)F-FDG PET preoperative staging of colorectal cancer:comparison with conventional staging and its impact on treatment decision making[J].J Nucl Med,2003,44(11):1784～1788
5[5]Gu J,Ma ZL,Li Y,et al.Routine(18) F-FDG PET preoperative staging of colorectal cancer:comparison with conventional staging and its impact on treatment decision making[J].J Nucl Med,2003,9(2):288～290
6[6]Tung SY and Wu CS.Clinical outcome of endoscopically removed early colorectal cancer[J].J Gastroenterol Hepatol,2003,18(10):1175～1179
7[7]Mamouns E,Wieand S,Wolmark N,et al.Comparative efficacy of adjuvant chemotherapy in patients with DukesB vereus DukesC colon cancer:results form four National Surgical Adjuvant Breast and Bowel Project adjuvant studies(C01,C02,C03 and C04)[J].J Clin Oncol,1999,17:1349～1355
8[8]Kuo LJ,Leu SY,Liu MC,et al.How aggressive should we be in patients with stage IV colorectal cancer[J]?Dis Colon Rectum,2003,46(12):1646～1652
9[9]Nozue M,Ohsiro Y,Kurate M,et al.Treatment and prognosis in colorectal cancer patients with bone metastasis[J].Oncology Reports,2002,9:109～112
10[10]Adam R,Pascal G,Azoulay D,et al.Liver resection for colorectal metastases:the third hepatectomy[J].Ann Surg,2003,238(6):871～883
同被引文献21
1Boocock DJ, Faust GE, Patel KR, et al. Phase Ⅰ dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a poten- tial cancer chemopreventive agent. Cancer Epidemiol Biomarkers Prey, 2007, 16(6): 1246-1252.
2Bouet-Toussaint F, Cabillic F, Toufirais O, et al. Vgamma9Vde- lta2 T cell-mediated recognition of human solid tumors. Potential for immunotherapy of hepatocellular and colorectal carcinomas. Cancer Immunol Immunother, 2008, 57(4) : 531-539.
3Jameson JM, Cauvi G, Sharp LL, et al. Gammadeha T cell-in- duced hyaluronan production by epithelial cells regulates inflam- mation. J Exp Med, 2005, 201 (8) : 1269-1279.
4Feng YH, Zhou WL, Wu QL, et al. Low dose of resveratrol en- hanced immune response of mice. Acta Pharmacol Sin, 2002, 23(10) : 893-897.
5McKenzie MD, Dudek NL, Mariana L, et al. Perforin and Fas in- duced by IFNgamma and TNFalpha mediate beta cell death by OT- Ⅰ CTL. Int Immunol, 2006, 18(6) : 837-846.
6Betts MR, Brenchley JM, Price DA, et al. Sensitive and viable identification of antigen-specific CD8^+ T cells by a flow eytometric assay for degranulation. J Immunol Methods, 2003, 281 (1-2) : 65-78.
7Hoshino R, Chatani Y, Yamori T, et al. Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene, 1999, 18(3) : 813-822.
8Black E J, Walker M, Clark W, et al. Cell transformation by v-Jun deactivates ERK MAP kinase signalling. Oncogene, 2002, 21 (42) : 6540-6548.
9Tang D, Wu D, Hirao A, et al. ERK activation mediates cell cy- cle arrest and apoptosis after DNA damage independently of p53. J Biol Chem, 2002, 277(15): 12710-12717.
10Chen D, Heath V, O'Garra A, et al. Sustained activation of the raf-MEK-ERK pathway elicits cytokine unresponsiveness in T cells. J Immunol, 1999, 163(11):5796-5805.
